Back to Search Start Over

Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort

Authors :
Bruyn, Alexander de
Montagnese, Federica
Holm-Yildiz, Sonja
Poulsen, Nanna Scharff
Stojkovic, Tanya
Behin, Anthony
Palmio, Johanna
Jokela, Manu
Bleecker, Jan L. De
Visser, Marianne de
Kooi, Anneke J. van der
Dam, Leroy ten
Domínguez González, Cristina
Maggi, Lorenzo
Gallone, Annamaria
Kostera-Pruszczyk, Anna
Macias, Anna
Łusakowska, Anna
Nedkova, Velina
Olive, Montse
Álvarez-Velasco, Rodrigo
Wanschitz, Julia
Paradas, Carmen
Mavillard, Fabiola
Querin, Giorgia
Fernández-Eulate, Gorka
Quinlivan, Ros
Walter, Maggie C.
Depuydt, Christophe E.
Udd, Bjarne
Vissing, John
Schoser, Benedikt
Claeys, Kristl G.
Bruyn, Alexander de
Montagnese, Federica
Holm-Yildiz, Sonja
Poulsen, Nanna Scharff
Stojkovic, Tanya
Behin, Anthony
Palmio, Johanna
Jokela, Manu
Bleecker, Jan L. De
Visser, Marianne de
Kooi, Anneke J. van der
Dam, Leroy ten
Domínguez González, Cristina
Maggi, Lorenzo
Gallone, Annamaria
Kostera-Pruszczyk, Anna
Macias, Anna
Łusakowska, Anna
Nedkova, Velina
Olive, Montse
Álvarez-Velasco, Rodrigo
Wanschitz, Julia
Paradas, Carmen
Mavillard, Fabiola
Querin, Giorgia
Fernández-Eulate, Gorka
Quinlivan, Ros
Walter, Maggie C.
Depuydt, Christophe E.
Udd, Bjarne
Vissing, John
Schoser, Benedikt
Claeys, Kristl G.
Publication Year :
2023

Abstract

Anoctamin-5 related muscle disease is caused by biallelic pathogenic variants in the anoctamin-5 gene (ANO5) and shows variable clinical phenotypes: limb-girdle muscular dystrophy type 12 (LGMD-R12), distal muscular dystrophy type 3 (MMD3), pseudometabolic myopathy or asymptomatic hyperCKaemia. In this retrospective, observational, multicentre study we gathered a large European cohort of patients with ANO5-related muscle disease to study the clinical and genetic spectrum and genotype–phenotype correlations. We included 234 patients from 212 different families, contributed by 15 centres from 11 European countries. The largest subgroup was LGMD-R12 (52.6%), followed by pseudometabolic myopathy (20.5%), asymptomatic hyperCKaemia (13.7%) and MMD3 (13.2%). In all subgroups, there was a male predominance, except for pseudometabolic myopathy. Median age at symptom onset of all patients was 33 years (range 23–45 years). The most frequent symptoms at onset were myalgia (35.3%) and exercise intolerance (34.1%), while at last clinical evaluation most frequent symptoms and signs were proximal lower limb weakness (56.9%) and atrophy (38.1%), myalgia (45.1%) and atrophy of the medial gastrocnemius muscle (38.4%). Most patients remained ambulatory (79.4%). At last evaluation, 45.9% of patients with LGMD-R12 additionally had distal weakness in the lower limbs and 48.4% of patients with MMD3 also showed proximal lower limb weakness. Age at symptom onset did not differ significantly between males and females. However, males had a higher risk of using walking aids earlier (P = 0.035). No significant association was identified between sportive versus non-sportive lifestyle before symptom onset and age at symptom onset nor any of the motor outcomes. Cardiac and respiratory involvement that would require treatment occurred very rarely. Ninety-nine different pathogenic variants were identified in ANO5 of which 25 were novel. The most frequent variants were c.191dupA (p.Asn64Lysfs*15) (57.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1431964468
Document Type :
Electronic Resource